SGLT2 inhibitors ameliorate DKD via hemodynamic and metabolic mechanisms such as improvement of tubuloglomerular feedback (Cherney et al., 2014; Kidokoro et al., 2019) and the suppression of claudin-1 in podocytes as a result of SIRT1 upregulation (Hasegawa et al., 2013). This evidence concerns the gene SIRT1 and diabetic kidney disease.